Discover Portal

Discover the latest research

Results 1 - 4 of 4 (0.0 secs)
NIHR Signal Albumin administrations can prolong survival for some people with liver disease
Weekly intravenous albumin can prolong the life for people with liver cirrhosis and uncomplicated ascites. Over about 18 months, 17% of patients given albumin died compared with 22% given standard care alone over 11 months. People with very severe (end-stage) cirrhosis develop various complications including a build-up of fluid in the abdomen (ascites). This is the first large trial to study the effects of long-term albumin infusions. In addition to improved survival, albumin also reduced hosp...
NIHR Signal Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs
A combination of providing clean needles and syringes and offering safer oral therapy, such as methadone, reduced the predicted risk of becoming infected with hepatitis C virus by 71%. Providing both services to people who inject drugs was likely to be cost-effective and has the potential to be cost-saving in some parts of the UK, depending on the size of the local population of people who inject drugs and underlying rates of infection. Current services are estimated to save up to £54 mil...
NIHR Signal Tenofovir reduces mother-to-child hepatitis B transmission
Giving pregnant women with hepatitis B the drug tenofovir reduced the likelihood of passing the infection on to their baby by about 80% and did not have any adverse impact on mother or child. Hepatitis B often doesn't cause any obvious symptoms in adults and typically passes in a few months without treatment, but in children it often persists for years and may cause progressive liver damage with cirrhosis and increased risk of liver cancer. Babies can get the infection from their mother dur...
NIHR Signal Two drug treatments for severe alcoholic hepatitis do not improve survival rates
This NIHR funded trial found that neither prednisolone nor pentoxifylline improved mortality for people with severe alcoholic hepatitis. No differences were found in mortality at 28 or 90 days, or in the need for liver transplant at one year. Overall mortality was high. Nearly three in ten people died before 90 days and more than half (56%) at one year. This shows that other new treatments are needed and more needs to be done to encourage complete abstinence from alcohol following severe alcohol...
1-4 / 4
search results
1 - 4 in 0.000 seconds
Publication Type
  •  4 
  •  3 
  •  2 
  •  1 
  •  1 

Show more (5)

View RSS Feed

Create an RSS feed based on your search.
This will update as new items are added.

Click here